A 4-year-old female presents with dysuria, urinary frequency, and new daytime accidents for 2 days. She is afebrile, active, and eating normally. Her mother reports bubble baths several times per week and says the child wipes independently. Abdominal exam is benign, and there is no flank pain. What is the most appropriate next step?

A 6-year-old female is brought in for a pruritic rash behind both knees and on the antecubital fossae. Her mother reports the rash worsens in winter and after hot baths. The child has a history of allergic rhinitis, and exam shows dry skin with erythematous plaques and excoriations. What is the most appropriate next step?

A 16-year-old female presents requesting contraception. She is sexually active, has migraine with aura, and reports occasional cigarette use. She prefers a method that does not require daily adherence. Which option is most appropriate?

Part 1 – Merck & Co. Inc: Merck & Co., Inc. is an American multinational pharmaceutical company. Below is information excerpted from Merck & Co. Inc.’s 10-K disclosure on various issues for the 2017 fiscal year.  (A) Investigations As previously disclosed, in November 2014, the Company was advised by the staff of the SEC that it was commencing an informal inquiry concerning Vioxx. On January 28, 2015, the Company announced that it received notice that the SEC issued a formal notice of investigation. Also, the Company has received subpoenas from the U.S. Department of Justice (the “DOJ”) requesting information related to the Company’s research, marketing and selling activities with respect to Vioxx in a federal health care investigation under criminal statutes. In addition, as previously disclosed, investigations are being conducted by local authorities in certain cities in Europe in order to determine whether any criminal charges should be brought concerning Vioxx. The Company is cooperating with these governmental entities in their respective investigations (the “Vioxx Investigations”). The Company cannot predict the outcome of these inquiries; however, they could result in potential civil and/or criminal dispositions. As previously disclosed, the Company has received a number of Civil Investigative Demands (“CID”) from a group of Attorneys General from 31 states and the District of Columbia who are investigating whether the Company violated state consumer protection laws when marketing Vioxx. The Company is cooperating with the Attorneys General in responding to the CIDs. In addition, the Company received a subpoena in September 2016 from the State of California Attorney General seeking documents and information related to the placement of Vioxx on California’s Medi-Cal formulary. The Company is cooperating with the Attorney General in responding to the subpoena.   (B) Reserves The Company currently anticipates that a number of Vioxx Product Liability Lawsuits will be tried throughout 2017. A trial in the Oregon securities case is scheduled for 2017, but the Company cannot predict whether this trial will proceed on schedule or the timing of any of the other Vioxx Shareholder Lawsuit trials. The Company believes that it has meritorious defenses to the Vioxx Lawsuits and will vigorously defend against them. In view of the inherent difficulty of predicting the outcome of litigation, particularly where there are many claimants and the claimants seek indeterminate damages, the Company is unable to predict the outcome of these matters, and at this time cannot reasonably estimate the possible loss or range of loss with respect to the Vioxx Lawsuits. The Company has not established any reserves for any potential liability relating to the Vioxx Lawsuits or the Vioxx Investigations, including for those cases in which verdicts or judgments have been entered against the Company, and are now in post-verdict proceedings or on appeal. In each of those cases the Company believes it has strong points to raise on appeal and therefore that unfavorable outcomes in such cases are not probable. Unfavorable outcomes in the Vioxx Litigation (as defined below) could have a material adverse effect on the Company’s financial position, liquidity and results of operations.   Required: Given the disclosures about the investigations instigated by the SEC and the DOJ, how do you think investors would respond to these disclosures about the investigations and reserves (be specific).

Managers’ Response to a New Standard: In 2004, the Financial Accounting Standards Board (FASB) revised SFAS 123 to mandate the expensing of employee stock option grants, but firms had until 2006 to adopt the mandate. The delay between the passage of the new rule and its mandated adoption date provided managers with the opportunity to take two very different paths. The first path was the acceleration of the vesting of executive stock options prior to the SFAS 123R effective date (accelerators), which reduced the number of options the firms had to expense after the SFAS 123R mandatory adoption date. Managers took this path to avoid reporting lower earnings after the SFAS 123R mandatory adoption date. An alternative path was the early adoption of SFAS 123R, whereby managers started to recognize the expenses associated with SFAS 123R earlier than required (early-adopters).  An academic study found evidence that in the period before early adoption, there were no significant differences in audit fees across the two groups of firms – early-adopters and accelerators. However, following the early adoption period, audit fees were significantly lower for early adopters, and significantly higher for accelerators. Further, the study documented significant positive abnormal returns at the early adoption announcements and significant negative abnormal returns at the acceleration announcements. Required: Using your knowledge of capital markets, explain why a company’s reporting choices around this new standard could impact audit fees and stock prices.

Convert the measurement. 28 L to milliliters

Write the percent as a fraction or mixed number in simplest form. 10%

Convert the measurement. Round to two decimal places. 140 pounds to kilograms 

The pictograph shows the annual number of wildfires in a region between 2000 and 2005.  What was the total annual number of wildfires from 2002 to 2003?

Find the unit price.   $54 for 5 books